Back to search

Article

Pneumocystis jiroveci pneumonia secondary to blinatumomab therapy: a case report

2023-11-24

Abstract excerpt

<h4>Background: </h4> With the increasing use of Blinatumomab in relapsed or refractory, as well as MRD-positive, B-cell precursor acute lymphoblastic leukemia (ALL), the recognition of its adverse effects has gradually improved, in which pneumocystis jiroveci pneumonia (PCP) is rare. Case presentation We present a case of PCP in patients undergoing Blinatumomab therapy. A 70-year-old female patient diagnosed wit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
46a0936a-5429-5b3c-b6d0-a85a184b6546
DOI
10.21203/rs.3.rs-3600239/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pneumocystis jiroveci pneumonia secondary to blinatumomab therapy: a case reportDOI 10.21203/rs.3.rs-3600239/v1
Select a neighboring publication to make it the new centre.